REGISTER RECORD · clinicaltrials.gov
NCT04478266
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | TERMINATED: terminated before completion |
|---|---|
| Register last updated | 2025-09-11 |
| Retrieved by this site | 2026-10-03 |
| Source | https://clinicaltrials.gov/study/NCT04478266 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.